Patents Examined by Robert S Cabral
-
Patent number: 12655237Abstract: The invention relates to a surface gradient cross-linked method of a ultra-high molecular weight polyethylene and the application thereof. The surface gradient crosslinked method of ultrahigh molecular weight polyethylene includes a n ultra-high molecular weight polyethylene surface photoinitiator diffusion step and an ultraviolet light irradiation crosslinking step. In this method, the photoinitiator is diffused deeply into the surface of ultra-high molecular weight polyethylene, the body material shows a gradient cross-linking from the surface to the inside after ultraviolet irradiation so that the whole bulk has a high toughness and the surface there of has a high wear resistance.Type: GrantFiled: February 26, 2024Date of Patent: June 16, 2026Assignees: B-ONE MEDICAL (SUZHOU) CO., LTD., B-ONE MEDICAL BIOTECH CORPORATION, B-ONE ORTHO, CORPInventor: Zongtao Zhang
-
Patent number: 12649776Abstract: The present invention relates to proteins suitable for being used as scaffolds to which a peptide of interest is bound, or which are comprised within a conjugate to which an agent of interest is attached. It also relates to said conjugates suitable for the selective delivery of their conjugated agents of interest to specific cell and tissue types, wherein said agent can be a therapeutic agent or an imaging agent. It also relates to nanoparticles comprising such conjugates and the therapeutic uses thereof.Type: GrantFiled: January 11, 2021Date of Patent: June 9, 2026Assignees: UNIVERSITAT AUTÒNOMA DE BARCELONA, NANOLIGENT, S.L., CONSORCIO CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED, FUNDACIÓ INSTITUT DE RECERCA DE L'HOSPITAL DE LA SANTA CREU I SANT PAUInventors: Esther Vázquez Gómez, Antonio Villaverde Corrales, Naroa Serna Romero, Juan Cedano Rodríguez, Olivia Cano Garrido, Ugutz Unzueta Elorza, Ramón Mangues Bafalluy, Patricia Virginia Álamo Vargas, Eloi Parladé Molist
-
Patent number: 12642876Abstract: The present disclosure provides, inter alia, novel compounds targeting cholecystokinin-2 receptor (CCK2R) expressed on the surface of cancer cells. Also provided are methods for imaging, diagnosing, and/or treating cancers using the same.Type: GrantFiled: October 30, 2025Date of Patent: June 2, 2026Assignee: Perspective Therapeutics, Inc.Inventors: Dijie Liu, Mengshi Li, Nicholas Baumhover, M M Hasibuzzaman, Dulanjali Thennakoon, Zhiming Dai, Michael K. Schultz
-
Patent number: 12643855Abstract: The present disclosure relates to a novel fluorogenic dimer compound, useful as a probe for detection of endogenous receptors, in particular G protein-coupled receptors. The present invention provides compositions and kits comprising such compound and methods of labeling a biomolecule, comprising the step of contacting the biomolecule with the compound of the invention.Type: GrantFiled: May 12, 2021Date of Patent: June 2, 2026Assignees: UNIVERSITE DE STRASBOURG, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Julie Karpenko, Andrey Klymchenko, Dominique Bonnet, Mayeul Collot
-
Patent number: 12630590Abstract: Disclosed herein are partially ordered polypeptides, which include a plurality of disordered domains and a plurality of structured domains. The partially ordered polypeptides may have phase transition behavior and form aggregates at, above, or below certain temperatures. Further provided are cellular scaffolds comprised of the partially ordered polypeptides.Type: GrantFiled: April 19, 2023Date of Patent: May 19, 2026Assignee: Duke UniversityInventors: Ashutosh Chilkoti, Stefan Roberts
-
Patent number: 12629535Abstract: Apparatus and methods are described for use with a heating device (26) configured to heat at least a portion of a subject's body. A nanoparticle (22) is configured to be administered to the subject, the nanoparticle including at least one inner core (30) that includes a magnetic material having a Curie temperature; a phase-change-material layer (31) that surrounds the inner core and that comprises a phase-change material that is configured to absorb latent heat of fusion by undergoing a phase change selected from the group consisting of: solid to liquid, and gel to liquid, the phase-change occurring at a phase-change temperature that is lower than the Curie temperature; and an outer layer (32) disposed around the phase-change-material layer, the outer layer comprising a plurality of nano-subparticles (34) that are separated from one another, such as to form a segmented layer. Other applications are also described.Type: GrantFiled: February 20, 2018Date of Patent: May 19, 2026Assignee: NEW PHASE LTD.Inventors: Raphael Hof, Raz Khandadash, Sarah Kraus, Pazit Rukenstein
-
Patent number: 12622867Abstract: The present invention relates to ultrasound mediated delivery of therapeutic agents to the pancreas, and particularly for treatment of pancreatic cancer such as pancreatic ductal adenocarcinoma (PDAC). More particularly, the invention provides a cluster composition and a pharmaceutical composition, for use in delivery of therapeutic agents and for treatment of pancreatic cancers, including PDAC.Type: GrantFiled: October 23, 2020Date of Patent: May 12, 2026Assignee: EXACT THERAPEUTICS ASInventors: Per Christian Sontum, Andrew John Healey, Svein Kvale
-
Patent number: 12605472Abstract: Compositions and methods useful for the treatment of hemoglobinopathies and hematological diseases are disclosed herein. The compositions include an actinium-225 labeled anti-CD45 antibody (BC8) formulated as a single patient dose that is wholly deliverable to a patient in a single dose. The actinium-225 labeled anti-CD45 may be administered alone or in combination with additional therapeutic agents, such as other immunotherapeutics or a radiosensitizing agent, or additional therapeutic interventions, such as bone marrow transplant or adoptive cell therapies.Type: GrantFiled: September 17, 2020Date of Patent: April 21, 2026Assignee: Actinium Pharmaceuticals, Inc.Inventors: Dale Ludwig, Sandesh Seth
-
Patent number: 12604892Abstract: The present invention relates to quaternary ammonium disinfecting cleaner compositions comprising a quaternary ammonium compound, an antimicrobial amine, and an anionic scale inhibitor. Beneficially, the compositions provide sanitizing efficacy without diminished performance and without scale formation when diluted with hard water. The compositions are suitable for inactivating and/or reducing infectious agents, particularly Norovirus, Adenovirus, and Polyomavirus.Type: GrantFiled: November 3, 2023Date of Patent: April 21, 2026Assignee: ECOLAB USA INC.Inventors: Carter M. Silvernail, Stefan Jaeger, Erin Jane Dahlquist Howlett, Michael Decker
-
Patent number: 12605403Abstract: Disinfecting compositions containing hypochlorous acid and acetic acid are useful for treating transient biofilms in or on tissue without harming the natural flora of the tissue. The compositions are useful for treating a variety of types of tissue. Compositions are useful for treating and preventing orally-associated biofilm. Compositions may be provided in mouthwash form, spray form, gel form, cream form, dentifrice form, and may include nanoparticle encapsulated molecules for controlled release.Type: GrantFiled: September 26, 2022Date of Patent: April 21, 2026Assignee: WIAB WATER INNOVATION ABInventor: Geir Hermod Almås
-
Patent number: 12599685Abstract: A tumor stroma imaging agent with a chemical structural formula (I): is provided, where R is hydrogen or fluorine. Compared with the prior art, the tumor stroma imaging agent exhibits significant affinity for fibroblast activation protein (FAP), high uptake for a malignant tumor with high FAP expression in a tumor stroma, and high sensitivity and specificity for the diagnosis of a malignant tumor, and is not prone to false positives. Therefore, the tumor stroma imaging agent can be effectively and safely used for the diagnosis and treatment of various malignant tumors with a prolonged half-life and an extended window period, which is conducive to clinical application.Type: GrantFiled: October 13, 2020Date of Patent: April 14, 2026Assignee: SHANGHAI UNIVERSITY OF MEDICINE & HEALTH SCIENCESInventors: Gang Huang, Bin Li
-
Patent number: 12599683Abstract: Nanoparticulate material suitable for administration to a subject, the nanoparticulate material having bound to its surface: (a) copolymeric steric stabiliser that promotes dispersion of the nanoparticulate material in a liquid, wherein the copolymeric steric stabiliser comprises (i) an anchoring polymer segment having one or more binding groups that bind the copolymeric steric stabiliser to the nanoparticulate material, and (ii) a steric stabilising polymer segment that is different from the anchoring polymer segment, and (b) copolymeric mapping moiety comprising (i) an anchoring polymer segment having one or more binding groups that bind the copolymeric mapping moiety to the nanoparticulate material, (ii) one or more mapping groups comprising an agent that specifically binds to fibroblast activation protein (FAP), and (iii) a coupling polymer segment that is different to the anchoring polymer segment, wherein the coupling polymer segment couples the anchoring polymer segment to the one or more mapping groupType: GrantFiled: May 12, 2022Date of Patent: April 14, 2026Assignees: Ferronova Pty LTDInventors: Benjamin Thierry, Melanie Ruth Maria Nelson, Valentina Milanova, Nicole Dmochowska, Thi Hanh Nguyen Pham, Brian Stanley Hawkett, Ramesh Mukkamala, Philip Stewart Low
-
Patent number: 12582728Abstract: The present disclosure provides compositions and methods for the detection and treatment of cancer. Specifically, the compositions of the present technology include novel radiohalogenated (e.g., radioiodinated) PSMA targeting agents and methods of using the same in diagnostic imaging as well as radiation therapy.Type: GrantFiled: August 28, 2020Date of Patent: March 24, 2026Assignee: Memorial Sloan Kettering Cancer CenterInventors: Naga Vara Kishore Pillarsetty, Teja Muralidhar Kalidindi, Sang Gyu Lee, Steven M. Larson, Jason S. Lewis, Serge Lyashchenko, Eva Burnazi
-
Patent number: 12582751Abstract: A sealing material suitable for a medical implant. The material includes a composite structure of a first component, a second component and a third component. The first component includes at least one biologically inert polymer. The second component includes a hydrogel, which swells up after contact with an aqueous solution by a first volume increase within a first time period. The third component includes a hygroscopic matrix, which swells up after contact with an aqueous solution by a second volume increase within a second time period. The second time period is shorter than the first time period.Type: GrantFiled: October 7, 2020Date of Patent: March 24, 2026Assignee: CORTRONIK GMBHInventors: Nicolas Degen, Sebastian Kaule, Sabine Illner, Stefanie Kohse, Niels Grabow, Klaus-Peter Schmitz
-
Patent number: 12576163Abstract: The present disclosure provides a fluorescent contrast agent with a targeting function, and a preparation method and a use thereof, and belongs to the technical fields of nanomaterials and biomedical materials. The fluorescent contrast agent (MR780 NPs) of the present disclosure can specifically bind to CD206 on a surface of tumor-associated macrophages (TAMs). MR780 NPs accumulate in lymph nodes invaded by tumor cells and undergo an oxidation-reduction reaction with reduced glutathione in a tumor microenvironment, which triggers a fluorescence signal of MR780 NPs; and MR780 NPs do not accumulate and do not show fluorescence in normal lymph nodes. Therefore, the fluorescent contrast agent of the present disclosure can be used to diagnose lymph node metastasis (LNM) of breast cancer, realize the preoperative evaluation of LNM, assist in the clinical determination of tumor staging and the formulation of a surgical plan, and achieve the accurate resection under intraoperative fluorescence navigation.Type: GrantFiled: April 29, 2022Date of Patent: March 17, 2026Assignees: Peking University Third Hospital, Ordos Clinical Medical College of Inner Mongolia. Medical UniversityInventors: Shumin Wang, Xiaolong Liang, Duo Zhao, Shiyuan Yang, Menghong Xu, Huiwen Li
-
Patent number: 12576166Abstract: We disclose a composition, comprising a compound, comprising a melanin precursor that spontaneously synthesizes a melanin when in free form in vivo, and a peptide directly covalently bonded to or indirectly linked to the melanin precursor, wherein the direct covalent bond or indirect link of the peptide to the melanin precursor blocks spontaneous synthesis of the melanin in vivo in the absence of protease activity. We also disclose methods of tumor imaging, tumor detection, diagnosis, and treatment, including methods comprising administering, to a patient suffering from a tumor, the composition; and either surgically resecting the tumor or thermally ablating the tumor, wherein the surgical resection is guided at least in part by contrast imparted by, or the thermally ablating targets cells containing, the melanin, wherein the melanin is spontaneously synthesized in the tumor after administering the composition.Type: GrantFiled: July 26, 2021Date of Patent: March 17, 2026Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventor: Mark D. Pagel
-
Patent number: 12550895Abstract: A multi-layer article includes a non-active state and an active state. The multi-layer article includes an outer layer with a first side and a second side, and at least one inner layer that is disposed adjacent to at least a portion of the outer layer and that includes a volatile material therein. The at least one inner layer is coupled to the outer layer in both the active state and the non-active state. The multi-layer article is folded along an axis so that an upper portion of the multi-layer article is disposed on a lower portion of the multi-layer article. The outer layer is a non-porous, non-permeable material that includes an aperture.Type: GrantFiled: May 28, 2025Date of Patent: February 17, 2026Assignee: S. C. JOHNSON & SON, INC.Inventors: Calistor Nyambo, Curtis R. Conklin, Caitlin Y. O'Gara, Jia Wang, Todd Ulrich
-
Patent number: 12551527Abstract: Lipid-based drug delivery vehicles (including liposomal nanoparticles) are described which include antibiotic(s) for the treatment of infections, such as Methicillin-Resistant Staphylococcus (S.) aureus (MRSA) infections and Methicillin-Susceptible S. aureus (MSSA) infections. These drug delivery vehicles have high drug-loading, do not accumulate in the liver, and can optionally include one or more targeting ligands.Type: GrantFiled: December 28, 2018Date of Patent: February 17, 2026Assignee: Wayne State UniversityInventors: Arun K. Iyer, Samaresh Sau, Michael Rybak, Ketki Bhise, Razie Kebriaei
-
Patent number: 12551581Abstract: A method of treating a cancer in a mammalian subject afflicted with the cancer, includes administering to the subject an immune checkpoint inhibitor, and administering to the subject a pentaaza macrocyclic ring complex corresponding to the formula (I) below, prior to, concomitantly with, or after administration of the immune checkpoint inhibitor, to increase the response of the cancer to the immune checkpoint inhibitor.Type: GrantFiled: December 30, 2021Date of Patent: February 17, 2026Assignee: Galera Labs, LLCInventors: Robert A. Beardsley, Jeffery L. Keene, Dennis P. Riley
-
Patent number: 12551501Abstract: Disinfecting compositions containing hypochlorous acid and acetic acid are useful for treating biofilms in or on tissue, including biofilms related to wounds or other skin trauma. The compositions are useful for treating a variety of types of tissue, both on the surface on beneath the surface of tissue. Compositions are provided for treating biofilms without inducing antimicrobial resistance.Type: GrantFiled: October 27, 2022Date of Patent: February 17, 2026Assignee: WIAB WATER INNOVATION ABInventor: Geir Hermod Almås